About the Congress
The 3rd International Congress of Cancer Genomics (CGC2026) will be held in Isfahan, May 2026. With an interdisciplinary focus on cancer biomarkers, molecular diagnosis, personalized medicine, targeted therapy, and the integration of artificial intelligence in cancer diagnosis and treatment, this congress marks an important step toward advancing knowledge and fostering the commercialization of innovative technologies in oncology.

This scientific and technological event brings together universities, pharmaceutical industries, research centers, investors, and knowledge-based companies active in molecular diagnosis and targeted cancer therapy. It provides a dynamic platform for collaboration among researchers, clinicians, data scientists, and entrepreneurs in the fields of bioinformatics, genetics, molecular biology, oncology, pharmacy, and data science.

With the rapid integration of artificial intelligence and machine learning in genomic data analysis, cancer detection, and personalized treatment design, CGC2026 offers a unique opportunity to explore the practical and forward-looking applications of these technologies in the early diagnosis, prognosis, and precision treatment of various cancers.

These emerging innovations are transforming the landscape of oncology — enabling more accurate diagnoses, faster decision-making, and highly effective therapies tailored to each patient’s genetic profile.

With trust in God and in pursuit of the congress’s scientific, clinical, and technological goals, we aim to take a meaningful step toward shaping the future of cancer medicine — improving patient outcomes, optimizing healthcare efficiency, and paving the way for a new era of intelligent, data-driven oncology.